Gébleux R et al. |
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. |
2015 |
Mol. Cancer Ther. |
pmid:26294742
|
Hamblett KJ et al. |
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. |
2015 |
Mol. Cancer Ther. |
pmid:25931519
|
Ab O et al. |
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. |
2015 |
Mol. Cancer Ther. |
pmid:25904506
|
Golfier S et al. |
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. |
2014 |
Mol. Cancer Ther. |
pmid:24714131
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Stefan N et al. |
Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. |
2017 |
Mol. Cancer Ther. |
pmid:28258164
|
Oroudjev E et al. |
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. |
2010 |
Mol. Cancer Ther. |
pmid:20937595
|
Zheng B et al. |
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. |
2009 |
Mol. Cancer Ther. |
pmid:19808977
|
Erickson HK et al. |
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. |
2012 |
Mol. Cancer Ther. |
pmid:22408268
|
Singh R et al. |
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. |
2016 |
Mol. Cancer Ther. |
pmid:27197308
|
Yan H et al. |
Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. |
2016 |
Mol. Cancer Ther. |
pmid:26712117
|
Cretella D et al. |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. |
2014 |
Mol. Cancer |
pmid:24898067
|
Werbovetz KA et al. |
Purification, characterization, and drug susceptibility of tubulin from Leishmania. |
1999 |
Mol. Biochem. Parasitol. |
pmid:10029309
|
Havens CG et al. |
Cellular effects of leishmanial tubulin inhibitors on L. donovani. |
2000 |
Mol. Biochem. Parasitol. |
pmid:11071278
|
Dagger F et al. |
Regulatory volume decrease in Leishmania mexicana: effect of anti-microtubule drugs. |
2013 |
Mem. Inst. Oswaldo Cruz |
pmid:23440120
|
Zuradelli M et al. |
Never too old to fight breast cancer: A case report. |
2018 |
Medicine (Baltimore) |
pmid:29489698
|
Vigne E and Sassoon I |
[The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. |
2014 |
Med Sci (Paris) |
pmid:25311020
|
Haeuw JF et al. |
[Immunoconjugates, drug-armed antibodies to fight against cancer]. |
2009 |
Med Sci (Paris) |
pmid:20035677
|
Jordan A et al. |
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. |
1998 |
Med Res Rev |
pmid:9664292
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24043217
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24662957
|
Mihály Z and Gyõrffy B |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. |
2013 |
Magy Onkol |
pmid:24107820
|
Dank M and Tõkés T |
[Monoclonal antibody therapy in breast cancer]. |
2013 |
Magy Onkol |
pmid:24107821
|
Segraves NL et al. |
An isolable acyclic hemiacetal of ansamitocin P-3. |
2012 |
Magn Reson Chem |
pmid:22374862
|
Meng H et al. |
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. |
2017 |
Macromol Biosci |
pmid:28464449
|
Storz U |
Antibody-drug conjugates: Intellectual property considerations. |
2015 |
MAbs |
pmid:26292154
|
Panowski S et al. |
Site-specific antibody drug conjugates for cancer therapy. |
2014 Jan-Feb |
MAbs |
pmid:24423619
|
Beck A and Reichert JM |
Antibody-drug conjugates: present and future. |
2014 Jan-Feb |
MAbs |
pmid:24423577
|
Whiteman KR et al. |
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. |
2014 Mar-Apr |
MAbs |
pmid:24492307
|
Chen L et al. |
In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. |
2016 |
MAbs |
pmid:27380163
|
Beck A et al. |
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. |
2011 Jul-Aug |
MAbs |
pmid:21691144
|
Lutz RJ and Whiteman KR |
Antibody-maytansinoid conjugates for the treatment of myeloma. |
2009 Nov-Dec |
MAbs |
pmid:20068397
|
Beck A et al. |
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. |
2012 Nov-Dec |
MAbs |
pmid:22909934
|
Thudium K et al. |
American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. |
2013 Jan-Feb |
MAbs |
pmid:23255090
|
Catcott KC et al. |
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. |
2016 |
MAbs |
pmid:26752675
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. |
2014 |
Lancet Oncol. |
pmid:24793816
|
Gnant M et al. |
HER2-positive breast cancer: a new piece of the puzzle. |
2014 |
Lancet Oncol. |
pmid:24793817
|
Yaqub F |
T-DM1 for HER2-positive metastatic breast cancer. |
2013 |
Lancet Oncol. |
pmid:23580966
|
Montemurro F |
Trastuzumab emtansine in HER2-positive metastatic breast cancer. |
2017 |
Lancet Oncol. |
pmid:28526537
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526538
|
Diéras V et al. |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526536
|
Hurvitz SA et al. |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. |
2018 |
Lancet Oncol. |
pmid:29175149
|
Thuss-Patience PC et al. |
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. |
2017 |
Lancet Oncol. |
pmid:28343975
|
Venkatesa P |
NICE recommends routine NHS funding for Kadcyla. |
2017 |
Lancet Oncol. |
pmid:28648556
|
Elsada A et al. |
NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. |
2016 |
Lancet Oncol. |
pmid:26703893
|
Venkatesan P |
Trastuzumab emtansine for HER2-positive breast cancer. |
2016 |
Lancet Oncol. |
pmid:27866859
|
Loibl S and Gianni L |
HER2-positive breast cancer. |
2017 |
Lancet |
pmid:27939064
|
Dholaria B and Srinivasan S |
T-DM1-related carotenoderma and hand-foot syndrome. |
2015 |
Lancet |
pmid:25933279
|
Kashiwaba M et al. |
A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. |
2016 |
Jpn. J. Clin. Oncol. |
pmid:26917603
|
Yamamoto H et al. |
Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. |
2015 |
Jpn. J. Clin. Oncol. |
pmid:25332421
|
Okamoto K et al. |
Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. |
1992 |
Jpn. J. Cancer Res. |
pmid:1517150
|
Hayashi T et al. |
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. |
2015 |
J. Urol. |
pmid:26047983
|
Fellous A et al. |
Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. |
1994 |
J. Protein Chem. |
pmid:7986343
|
Xie H et al. |
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. |
2004 |
J. Pharmacol. Exp. Ther. |
pmid:14634038
|
Kupchan SM et al. |
The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. |
1977 |
J. Org. Chem. |
pmid:874612
|
Bartsch R et al. |
Breast cancer brain metastases responding to primary systemic therapy with T-DM1. |
2014 |
J. Neurooncol. |
pmid:24065570
|
Geraud A et al. |
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:27995546
|
de Vries CL et al. |
Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. |
2016 |
J. Neurooncol. |
pmid:26732082
|
Altundag K |
Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:28337582
|
Sato Y et al. |
Induction of neurofibrillary tangles in cultured mouse neurons by maytanprine. |
1985 |
J. Neurol. Sci. |
pmid:4040155
|
Cosmai L et al. |
Renal toxicity of anticancer agents targeting HER2 and EGFR. |
2015 |
J. Nephrol. |
pmid:26341657
|
Alabaster O and Cassidy M |
Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. |
1978 |
J. Natl. Cancer Inst. |
pmid:625068
|
Eagan RT et al. |
Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. |
1978 |
J. Natl. Cancer Inst. |
pmid:628025
|
Schwarz LJ et al. |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. |
2017 |
J. Natl. Cancer Inst. |
pmid:29059433
|
Azvolinsky A |
Conjugating antibodies to cytotoxic agents: getting the best of both worlds? |
2013 |
J. Natl. Cancer Inst. |
pmid:24244034
|
Tuma RS |
Enthusiasm for antibody-drug conjugates. |
2011 |
J. Natl. Cancer Inst. |
pmid:21972230
|
Gupta RS |
Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. |
1985 |
J. Natl. Cancer Inst. |
pmid:3855475
|
Aldrich CD |
Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. |
1979 |
J. Natl. Cancer Inst. |
pmid:224236
|
Askoxylakis V et al. |
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. |
2016 |
J. Natl. Cancer Inst. |
pmid:26547932
|
Sakai K et al. |
Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. |
1988 Sep-Oct |
J. Nat. Prod. |
pmid:3204376
|
Novelo M et al. |
Cytotoxic constituents from Hyptis verticillata. |
1993 |
J. Nat. Prod. |
pmid:8277312
|
Perdue RE |
KB cell culture I. Role in discovery of antitumor agents from higher plants. |
1982 Jul-Aug |
J. Nat. Prod. |
pmid:7130986
|
Kusari S et al. |
Endophytes are hidden producers of maytansine in Putterlickia roots. |
2014 |
J. Nat. Prod. |
pmid:25478947
|
Snipes CE et al. |
The ansacarbamitocins: polar ansamitocin derivatives. |
2007 |
J. Nat. Prod. |
pmid:17892263
|
Tan GT et al. |
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. |
1991 Jan-Feb |
J. Nat. Prod. |
pmid:1710653
|
Kuo YH et al. |
Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. |
1990 Mar-Apr |
J. Nat. Prod. |
pmid:2380715
|
Kupchan SM et al. |
Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. |
1978 |
J. Med. Chem. |
pmid:563462
|
Zhao RY et al. |
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. |
2011 |
J. Med. Chem. |
pmid:21517041
|
Pillow TH et al. |
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. |
2014 |
J. Med. Chem. |
pmid:25191794
|
Lambert JM and Chari RV |
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. |
2014 |
J. Med. Chem. |
pmid:24967516
|
Widdison WC et al. |
Semisynthetic maytansine analogues for the targeted treatment of cancer. |
2006 |
J. Med. Chem. |
pmid:16821799
|
Ng D et al. |
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. |
2009 |
J. Ind. Microbiol. Biotechnol. |
pmid:19609582
|
Gao Y et al. |
Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. |
2014 |
J. Ind. Microbiol. Biotechnol. |
pmid:24174216
|
Dillon RL et al. |
Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. |
2016 |
J. Immunother. |
pmid:26938945
|
Tanida S et al. |
Ansamitocin-induced synchrony in Tetrahymena pyriformis. |
1980 |
J. Gen. Microbiol. |
pmid:6777454
|
Yue W et al. |
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. |
2013 |
J. Exp. Ther. Oncol. |
pmid:24416991
|
La Monica S et al. |
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
2017 |
J. Exp. Clin. Cancer Res. |
pmid:29202823
|
Feng L et al. |
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. |
2016 |
J. Exp. Clin. Cancer Res. |
pmid:27102688
|
Krop IE et al. |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. |
2015 |
J. Clin. Oncol. |
pmid:25713436
|
Harbeck N et al. |
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. |
2017 |
J. Clin. Oncol. |
pmid:28682681
|
Miller KD et al. |
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. |
2014 |
J. Clin. Oncol. |
pmid:24733796
|
Mahtani RL and Vogel CL |
When Can a Salvage Therapy (T-DM1) Take the Lead? |
2016 |
J. Clin. Oncol. |
pmid:27432926
|
Galsky MD et al. |
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. |
2008 |
J. Clin. Oncol. |
pmid:18362364
|
Dzimitrowicz H et al. |
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. |
2016 |
J. Clin. Oncol. |
pmid:27298406
|
Tolcher AW et al. |
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. |
2003 |
J. Clin. Oncol. |
pmid:12525512
|
Isakoff SJ and Baselga J |
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. |
2011 |
J. Clin. Oncol. |
pmid:21172881
|
Burris HA et al. |
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. |
2011 |
J. Clin. Oncol. |
pmid:21172893
|
Diéras V et al. |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. |
2014 |
J. Clin. Oncol. |
pmid:25024070
|
Younes A et al. |
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. |
2012 |
J. Clin. Oncol. |
pmid:22753910
|
Hassan R et al. |
Mesothelin Immunotherapy for Cancer: Ready for Prime Time? |
2016 |
J. Clin. Oncol. |
pmid:27863199
|